Reviva Pharmaceuticals Holdings, INC 8-K filings

Reviva Pharmaceuticals reported Q2 2026 results, highlighting a new patent application for brilaroxazine aimed at extending exclusivity to 2046 and outlining Q4 2026 FDA feedback expectations.

Reviva Pharmaceuticals announced Q1 2026 financial results, highlighting a provisional patent filing for a new form of brilaroxazine aimed at extending exclusivity until 2046 and upcoming FDA feedback.

Reviva Pharmaceuticals Holdings, Inc. will have its common stock delisted from The Nasdaq Capital Market effective May 14, 2026, and will begin trading on the OTCQB Venture Market.

Reviva Pharmaceuticals announced updates on its brilaroxazine program, including efforts to extend patent life and prepare for the next phase of development.

Reviva reported a narrower 2025 net loss, raised $10M in March 2026, and will run a second Phase 3 trial for brilaroxazine before an NDA filing for schizophrenia.

Reviva Pharmaceuticals Holdings, Inc. announced the pricing of a public offering raising $10 million in gross proceeds to fund R&D and general corporate purposes.

Reviva Pharmaceuticals Holdings, Inc. announced a one-for-twenty reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Reviva Pharmaceuticals Holdings, Inc. has been granted an exception by Nasdaq to regain compliance with the $1.00 minimum bid price requirement until March 27, 2026.

Reviva Pharmaceuticals stockholders approved a significant increase in authorized common stock and a potential reverse stock split, while the FDA recommended an additional Phase 3 trial for brilaroxazine, pushing back its potential NDA filing.

Reviva Pharmaceuticals reported a reduced net loss in Q3 2025 and provided updates on its lead drug candidate, brilaroxazine, including plans for an FDA pre-NDA meeting and potential NDA submission for schizophrenia.

Reviva Pharmaceuticals Holdings, Inc. announced it has regained compliance with Nasdaq's minimum Market Value of Listed Securities requirement but continues to face non-compliance with the $1.00 minimum bid price.

Reviva Pharmaceuticals Holdings, Inc. has amended its bylaws to reduce the quorum required for stockholder meetings from a majority to one-third of voting power, effective September 26, 2025.

Reviva Pharmaceuticals Holdings, Inc. announced the pricing of a public offering of common stock and warrants, raising approximately $9 million in gross proceeds.

Reviva Pharmaceuticals reports successful completion of its Phase 3 OLE trial for brilaroxazine, targeting Q2 2026 NDA submission for schizophrenia.

Reviva Pharmaceuticals Holdings, Inc. has priced a public offering of common stock and accompanying Series C and Series D warrants, aiming to raise $10 million in gross proceeds to fund research and development and for general corporate purposes.

Reviva Pharmaceuticals Holdings, Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, effective June 3, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly, while also noting that prior audit reports included an explanatory paragraph regarding going concern uncertainty.

Reviva Pharmaceuticals Holdings, Inc. reported a positive full dataset and successful completion of its Phase 3 RECOVER open-label extension study, demonstrating sustained efficacy and a well-tolerated safety profile for brilaroxazine in schizophrenia patients over one year.

Reviva Pharmaceuticals Holdings, Inc. has entered into an At Market Issuance Sales Agreement with B. Riley Securities and Alliance Global Partners to potentially sell up to $50 million of its common stock.

Reviva Pharmaceuticals announced its first quarter 2025 financial results, reporting a net loss of $6.4 million and providing updates on its brilaroxazine clinical program.

Reviva Pharmaceuticals announces its full year 2024 financial results, highlighting positive clinical data from its brilaroxazine program and outlining anticipated milestones.

Reviva Pharmaceuticals' Compensation Committee approves salary increases, bonuses, and option grants for key executives, including the CEO, CFO, and VP of Program & Portfolio Management.

Reviva Pharmaceuticals has priced a public offering to raise $18 million through the sale of common stock and warrants.

Reviva Pharmaceuticals reports positive preliminary topline data from the open-label extension of its Phase 3 RECOVER trial, showing sustained efficacy and tolerability of brilaroxazine in schizophrenia patients over one year.

Reviva Pharmaceuticals has increased its authorized common stock shares from 115 million to 315 million following approval at its 2024 Annual Meeting of Stockholders.

Reviva Pharmaceuticals announced its third quarter 2024 financial results, highlighted clinical progress with its brilaroxazine program, and provided an update on key milestones.

Reviva Pharmaceuticals reports positive enrollment progress in its open-label extension study of brilaroxazine for schizophrenia, with topline data expected in December 2024.

Reviva Pharmaceuticals' Compensation Committee awarded fiscal 2023 incentive bonuses to its named executive officers and a vice president in the form of immediately vested stock options.

Reviva Pharmaceuticals has closed a public offering, generating $3.8 million in net proceeds, and amended existing warrants to lower their exercise price.

Reviva Pharmaceuticals announced the pricing of a $5 million underwritten offering of common stock and warrants, with proceeds intended for research and development and general corporate purposes.

Reviva Pharmaceuticals announced its second quarter 2024 financial results, highlighted by progress in its brilaroxazine clinical program and expansion of its patent portfolio.